SecBot SecBot
Biotech Drug Report Generated Aug 3, 2026

Humira

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since December 2002 in the US (FDA approval catalyst recorded for 2002-12-31); the originator franchise is in its late-life, biosimilar-eroded phase.
Why 3/10
Humira is approved and marketed with no pending FDA decision on the originator, its defining binary (original 2002 approval; US biosimilar entry in 2023) has long passed, and quarterly erosion is a known, priced factor at a ~$465B-cap company where Humira was only ~$756M of a $16.99B quarter, so no Humira-specific hard, dated catalyst exists in the next ~12 months; per the rubric that caps it at 3-5 and it sits at the low end.
Actionable Insight NEUTRAL

Treat Humira purely as an erosion/run-rate metric inside AbbVie's quarterly reports, expect continued -30%+ YoY declines and do not trade ABBV on Humira headlines, since the stock's thesis is driven by Skyrizi/Rinvoq growth, the Apogee close, and the broader pipeline. If you want Humira-specific exposure, the action is in the biosimilar makers, not the originator.

Price Chart

Loading chart...

Executive Summary

Humira (adalimumab) is AbbVie's blockbuster anti-inflammatory antibody, first approved by the FDA in 2002, whose US patent-era ended with biosimilar competition. It is now a shrinking legacy asset: Q2 2026 sales were $756M, down 35.9% year-over-year, versus Q2 total company revenue of $16.99B (+10.2%), with successors Skyrizi ($5.505B, +24.4%) and Rinvoq ($2.525B, +24.5%) already far outpacing it (AbbVie Q2 2026 8-K). The stock is a diversified mega-cap with strong analyst support (31 buy/strong-buy vs 0 sell; mean price target ~$270 vs last close ~$251), so Humira-specific news is unlikely to move ABBV materially, it is a watch-the-erosion-line item, not a catalyst.

How It Works

A biologic (laboratory-made antibody) given by injection that binds to and neutralizes tumor necrosis factor-alpha, a protein that drives inflammation. By blocking it, the drug dampens the joint, skin, and gut inflammation behind autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, and juvenile idiopathic arthritis (indications reflected in the clinical trials returned this session). The FDA label carries boxed warnings about increased risk of serious infections and malignancy.

Trial Status

No pivotal originator trials are running, Humira/adalimumab now appears mainly as an active COMPARATOR arm in Phase 2/3 trials (e.g., AbbVie's own upadacitinib-vs-adalimumab RA study NCT05814627; UCB's bimekizumab-vs-adalimumab psoriasis/psoriatic-arthritis studies). FDA actions show ongoing biosimilar activity on the molecule: Celltrion's adalimumab-aaty safety labeling (Jul 2026), Pfizer's Abrilada safety labeling (May 2026), and Samsung Bioepis' Hadlima (adalimumab-bwwd) supplemental approvals (May 2025).

The Two-Sided Case

▲ Bull Case4
Still generates real cash: Humira contributed $756M of revenue in Q2 2026 even while eroding -35.9% YoY (AbbVie Q2 2026 8-K), so the franchise is a cash cow in managed decline rather than a dead asset.
Erosion is fully offset by successors: same-quarter Skyrizi revenue $5.505B (+24.4%) and Rinvoq $2.525B (+24.5%) powered total revenue up 10.2% YoY (Q2 2026 8-K), so Humira's decline no longer threatens the company's growth story.
Street is broadly constructive on ABBV overall: consensus shows 22 buy + 9 strong buy vs 0 sell, mean price target $270.39 (≈11.6% above last close $250.94), with July 2026 target raises from Barclays ($300), BMO Capital ($300), Wells Fargo ($295), RBC and JPMorgan ($280).
Not a financing/going-concern risk: ABBV is a ~$465B market-cap company (market cap from Q2 2026 earnings report) with a 1.28% short position vs estimated shares outstanding (FINRA, 2026-07-15 settlement), no structural overhang on the name.
▼ Bear Case3
Deep, durable biosimilar competition: multiple adalimumab biosimilars are actively marketed and labeled, Celltrion's adalimumab-aaty (FDA safety labeling Jul 2026), Pfizer's Abrilada (May 2026), Samsung Bioepis' Hadlima (supplemental approvals May 2025), keeping -30%+ annual erosion on the originator.
Humira is now a small, shrinking slice of AbbVie: ~4.4% of Q2 2026 revenue ($756M of $16.99B), so its decline is a headwind that dilutes growth but that investors already fully discount, no upside left and continued downside to its run rate.
Patent-expired franchise with no regulatory upside: the originator has no pending label expansion or approval decision, so the only future Humira headlines are more erosion, more payer/rebate pressure, and possible further price concessions.

Upcoming Catalysts

  • No Humira-specific binary catalysts: the originator has no PDUFA, pivotal readout, or label-expansion decision pending.
  • Quarterly Humira erosion updates embedded in earnings, next report Q3 2026 (~late Oct 2026): watch whether YoY decline decelerates as the biosimilar shock matures.
  • Apogee Therapeutics acquisition (~$10.9B) expected to close in Q3 2026, a pipeline deal that matters far more to ABBV than Humira's run rate.
  • Continued FDA activity on adalimumab biosimilars (labeling/approvals) as a proxy for competitive intensity.
  • AbbVie pipeline readouts (e.g., ABBV-951 Parkinson's Phase 3 results pending), the real share-price drivers at this company.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 5

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov